Drug Developers Outsource Antibody Discovery to CROs
Increasing complexity in drug development spurs demand for outsourced antibody discovery services. Companies are engaging CROs to accelerate research workflows and manage costs.
February-March 2024 – Pharmaceutical companies are increasingly turning to external organizations for antibody discovery services to enhance their drug development pipelines. The growing complexity and demands of modern research and development are prompting many firms to engage Contract Research Organizations (CROs).
This shift is driven by a need for optimized research services, cost efficiencies, and access to specialized expertise. Antibodies are crucial in developing therapeutics, and their efficient identification and design are vital. CROs offer specialized capabilities to accelerate these processes, allowing drug developers to focus on other critical research areas.
The antibody discovery process involves multiple stages, from target validation to identifying a clinical candidate. Key steps include generating initial 'hits,' followed by screening and selecting lead molecules. These leads are then optimized through techniques such as humanization, affinity maturation, and Fc engineering before a final candidate is chosen.
Market research indicates that over 350 companies offer antibody discovery services and platforms. Hit generation services are the most common offering, typically constituting approximately 40% of an antibody discovery operation. Some providers aim to offer comprehensive, end-to-end solutions for the entire discovery process.